Abstract:8527 Background: KIT is an important oncogene in acral and mucosal melanomas, which account for 70% of melanomas in Asian patients (Pts). We conducted a phase II study (NCT00881049) to test the KIT inhibitor imatinib in metastatic melanoma pts with KIT aberrations. Methods: Pts with metastatic or unresectable melanoma whose tumor had KIT aberrations (KIT mutation [mut] and/or KIT gene DNA amplification [amp]) and who had measurable disease were enrolled. Pts received imatinib 400 mg/d continually until disease progression or intolerable toxicity. The dosage of Imatinib was escalated to 600 mg or 800 mg per day if progression was observed. Response was assessed monthly using RECIST criteria. The endpoints were progression-free survival (PFS), overall response rate (ORR) and toxicity. Results: Of 390 cases screened, 67 (17.4%) had a KIT mut or amp: 26/137 (18.9%) acral, 21/110 (19.1%) mucosal, 9/26 (34.6%) CSD, 6/75 (8%) NCSD, 5/42 (11.9%) unknown primary. 41 (10.5%) had a mut only; 23 (5.9%) had an amp only; 3 (0.8%) had both. Thus far, 28 patients have been treated with 26 pts currently evaluable: 5 stage M1a/3 M1b/20 M1c; median prior therapies: 2. Six patients (21%) achieved PR (5 mut, 1 amp, 4∼10+m); nine patients (35%) received SD (≥ 3 m, 3.5∼9+m). Pts who failed on 400mg also failed on escalation to 600mg and could not tolerate 800mg due to toxicities. Samples of new or progressive lesions were obtained from 5 PR pts after they failed on imatinib 400mg, and were analyzed in KIT, BRAF and PDGFRA. In one pt (emerging metastasis in liver) new mutations were found in BRAF (V600E) and PDGFRA (W559stop) which were wild-type before treatment, and loss of the KIT mutation present at baseline. Common toxicities at 400 mg were rash, vomiting, edema and myelosuppresion. Conclusions: Imatinib (400mg/d) provides a beneficial therapeutic effect for a significant proportion of Chinese metastatic melanoma pts with KIT aberrations. Acquired genetic mutations after treatment may account for emergence of resistance in some pts. Supported by the National Natural Science Foundation of China (30973483), 985-2-085-113 and Novartis Oncology in China. No significant financial relationships to disclose.

Mtor Pathway Activation in Kit-Mutated Melanoma with Acquired Imatinib Resistance.

Mtorc1/autophagy-Regulated MerTK in Mutant BRAFV600 Melanoma with Acquired Resistance to BRAF Inhibition

A Phase Ii Study of Imatinib for Advanced Melanoma Patients with Kit Aberrations

Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to Pi3k-Akt-Mtor Pathway Inhibitors

815P A Single-Arm, Phase II Clinical Study of Imatinib Mesylate/toripalimab Combo in Patients (pts) with Advanced Melanoma Harboring C-Kit Mutation or Amplification

Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence from a Retrospective Study

Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma

Phase Ii, Open-Label, Single-Arm Trial Of Imatinib Mesylate In Patients With Metastatic Melanoma Harboring C-Kit Mutation Or Amplification

A Phase II Study of Everolimus for Advanced Melanoma Patients with Mtor Mutations.

Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma

Analysis of Mtor Mutations in Chinese Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.

Oncogenic Signaling Mechanisms in Imatinib-Resistant Gastrointestinal Stromal Tumor

Effect of Restoration of Microrna-18A on Improvement of Imatinib Therapy on Secondary Imatinib-Resistance Metastatic Melanoma.

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway

Secondary Resistance to Imatinib in Patients with Gastrointestinal Stromal Tumors Through an Acquired KIT Exon 17 Mutation.

[Secondary Mutation of C-Kit/pdgfrα Genotypes after Imatinib Mesylate Therapy and Its Relationship with Efficacy of Sunitinib].

c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis

Repurposing Ponatinib As a Potent Agent Against KIT Mutant Melanomas.

Efficacy and safety of Imatinib in the 78 patients with advanced melanoma harboring KIT mutation

Targeting Mitochondrial Biogenesis to Overcome Drug Resistance to MAPK Inhibitors